Pipeline
HUYA Development Compounds
HUYA identifies a select subset of promising early stage compounds from its product portfolio and positions them for development in Western markets. HUYA seeks opportunities in therapeutic areas with significant market potential and unmet medical need, where the compound has a competitive advantage, strong patent position worldwide, and a clear clinical development path.
HUYA performs preliminary diligence on many drug candidates to find the most promising opportunities that would benefit from added value. HUYA is currently working with a number of compounds, two of which are currently available for out-licensing: the novel anti-arrhythmic HBI-3000 and the potential first-in-class oncology drug HBI-8000.